ACKNOWLEDGEMENT
None
1. Dandana A, Ben Khelifa S, Chahed H, Miled A, Ferchichi S. Gaucher Disease: Clinical, Biological and Therapeutic Aspects. Pathobiol J Immunopathol Mol Cell Biol. 2016;83(1):13–23.
2. Bremova-Ertl T, Schiffmann R, Patterson MC, Belmatoug N, Billette de Villemeur T, Bardins S, et al. Oculomotor and Vestibular Findings in Gaucher Disease Type 3 and Their Correlation with Neurological Findings. Front Neurol. 2017;8:711.
3. Esteban O, Torralba MA, Olivera S, Martinez M, Montes P, Marco S, et al. New correlations between ocular parameters and disease severity in Spanish patients with Gaucher’s disease Type I. PloS One. 2021;16(12):e0260241.
4. Accardo A, Bembi B, Pensiero S, Perissutti P. Type 3 Gaucher’s disease in a three-year-old child: saccadic eye movements analysis. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus. 2005 Oct;9(5):501–3.
5. Grabowski GA. Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test. 1997;1(1):5–12.
6. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000 Oct 9;160(18):2835–43.
7. Kaplan P, Baris H, De Meirleir L, Di Rocco M, El-Beshlawy A, Huemer M, et al. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr. 2013 Apr;172(4):447–58.
8. Puri RD, Kapoor S, Kishnani PS, Dalal A, Gupta N, Muranjan M, et al. Diagnosis and Management of Gaucher Disease in India - Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. Indian Pediatr. 2018 Feb 15;55(2):143–53.
9. Weinreb NJ, Goker-Alpan O, Kishnani PS, Longo N, Burrow TA, Bernat JA, et al. The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here? Mol Genet Metab. 2022 May;136(1):4–21.
10. Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab. 2018 Mar;13(2):107–18.
11. Gupta N, Oppenheim IM, Kauvar EF, Tayebi N, Sidransky E. Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis. 2011 Jan 15;46(1):75–84.
12. Roshan Lal T, Sidransky E. The Spectrum of Neurological Manifestations Associated with Gaucher Disease. Dis Basel Switz. 2017 Mar 2;5(1):10.
13. Wang HP, Wong LC, Hsu CJ, Hu SC, Chu YJ, Lee WT. Eye motor manifestations in children with neurometabolic disorders. J Formos Med Assoc Taiwan Yi Zhi. 2022 Apr;121(4):736–48.
14. Hopf S, Pfeiffer N, Liesenfeld M, Mengel KE, Hennermann JB, Schmidtmann I, et al. A comprehensive monocentric ophthalmic study with Gaucher disease type 3 patients: vitreoretinal lesions, retinal atrophy and characterization of abnormal saccades. Orphanet J Rare Dis. 2019 Nov 14;14(1):257.